Blue Fin Capital’s AbbVie ABBV Stock Holding History

Blue Fin Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.58M	Buy	16,445 +147	+0.9%	+$32.6K	0.59%	37
2025 Q4	$3.72M	Sell	16,298 -138	-0.8%	-$31.4K	0.58%	34
2025 Q3	$3.81M	Sell	16,436 -91	-0.6%	-$18.5K	0.6%	34
2025 Q2	$3.07M	Buy	16,527 +1,017	+7%	+$189K	0.52%	38
2025 Q1	$3.25M	Buy	15,510 +784	+5%	+$152K	0.63%	34
2024 Q4	$2.62M	Sell	14,726 -16	-0.1%	-$2.94K	0.48%	40
2024 Q3	$2.91M	Buy	14,742 +64	+0.4%	+$11.9K	0.55%	40
2024 Q2	$2.52M	Buy	14,678 +275	+2%	+$45.6K	0.5%	40
2024 Q1	$2.62M	Sell	14,403 -62	-0.4%	-$10.7K	0.58%	39
2023 Q4	$2.24M	Buy	14,465 +99	+0.7%	+$14.4K	0.58%	38
2023 Q3	$2.14M	Buy	14,366 +111	+0.8%	+$16.3K	0.63%	37
2023 Q2	$1.92M	Sell	14,255 -14	-0.1%	-$2.05K	0.55%	41
2023 Q1	$2.1M	Sell	14,269 -12	-0.1%	-$1.83K	0.68%	35
2022 Q4	$2.31M	Buy	14,281 +42	+0.3%	+$6.44K	0.85%	36
2022 Q3	$1.91M	Buy	14,239 +817	+6%	+$117K	0.72%	39
2022 Q2	$2.06M	Buy	13,422 +115	+0.9%	+$17.6K	0.73%	40
2022 Q1	$2.16M	Buy	13,307 +229	+2%	+$33.3K	0.63%	42
2021 Q4	$1.77M	Buy	13,078 +487	+4%	+$57.5K	0.49%	50
2021 Q3	$1.36M	Sell	12,591 -76	-0.6%	-$8.68K	0.41%	55
2021 Q2	$1.43M	Sell	12,667 -713	-5%	-$80.3K	0.44%	56
2021 Q1	$1.45M	Sell	13,380 -37	-0.3%	-$3.96K	0.5%	55
2020 Q4	$1.44M	Buy	13,417 +378	+3%	+$36.3K	0.51%	52
2020 Q3	$1.14M	Sell	13,039 -97	-0.7%	-$9.13K	0.46%	56
2020 Q2	$1.29M	Sell	13,136 -152	-1%	-$13.4K	0.57%	50
2020 Q1	$1.01M	Sell	13,288 -646	-5%	-$55K	0.56%	54
2019 Q4	$1.23M	Sell	13,934 -23	-0.2%	-$1.91K	0.58%	55
2019 Q3	$1.06M	Sell	13,957 -975	-7%	-$66.8K	0.55%	60
2019 Q2	$1.08M	Buy	14,932 +85	+0.6%	+$6.68K	0.56%	60
2019 Q1	$1.2M	Sell	14,847 -694	-4%	-$56.8K	0.63%	50
2018 Q4	$1.43M	Sell	15,541 -372	-2%	-$32.7K	0.86%	33
2018 Q3	$1.5M	Sell	15,913 -191	-1%	-$18.1K	0.75%	38
2018 Q2	$1.49M	Buy	16,104 +1,355	+9%	+$132K	0.8%	33
2018 Q1	$1.4M	Sell	14,749 -355	-2%	-$39K	0.79%	34
2017 Q4	$1.46M	Buy	15,104 +140	+0.9%	+$13.2K	0.85%	34
2017 Q3	$1.33M	Sell	14,964 -214	-1%	-$16.3K	0.81%	36
2017 Q2	$1.1M	Sell	15,178 -922	-6%	-$62K	0.71%	43
2017 Q1	$1.05M	Sell	16,100 -500	-3%	-$31.4K	0.64%	47
2016 Q4	$1.04M	Buy	16,600 +975	+6%	+$59.5K	0.69%	47
2016 Q3	$985K	Sell	15,625 -185	-1%	-$12K	0.8%	41
2016 Q2	$979K	Sell	15,810 -200	-1%	-$12.2K	0.81%	43
2016 Q1	$914K	Sell	16,010 -485	-3%	-$27K	0.78%	45
2015 Q4	$977K	Sell	16,495 -135	-0.8%	-$7.78K	0.75%	45
2015 Q3	$905K	Sell	16,630 -300	-2%	-$19.5K	0.7%	46
2015 Q2	$1.14M	Hold	16,930	–	–	0.82%	37
2015 Q1	$991K	Buy	16,930 +40	+0.2%	+$2.42K	0.72%	45
2014 Q4	$1.1M	Sell	16,890 -125	-0.7%	-$7.88K	0.83%	40
2014 Q3	$983K	Buy	17,015 +30	+0.2%	+$1.67K	0.78%	42
2014 Q2	$959K	Sell	16,985 -255	-1%	-$13.4K	0.77%	45
2014 Q1	$886K	Sell	17,240 -376	-2%	-$19K	0.78%	43
2013 Q4	$930K	Buy	+17,616	New	+$866K	0.83%	38

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Blue Fin Capital's ABBV Position: Q1 2026 in Review

Blue Fin Capital increased its AbbVie (ABBV) stake by 0.9% in Q1 2026, buying an estimated $32.6K and bringing the position to 16,445 shares worth $3.58M. The position accounts for 0.59% of the portfolio, ranked #37.

Blue Fin Capital first reported a position in ABBV in Q4 2013 and has held it in 50 quarters since. The position peaked at $3.81M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Blue Fin Capital held 16,445 shares of AbbVie worth $3.58M as of Q1 2026.
Blue Fin Capital bought 147 AbbVie shares in Q1 2026, an estimated $32.6K.
AbbVie made up 0.59% of Blue Fin Capital's portfolio in Q1 2026, its #37 holding.
Blue Fin Capital first reported a position in AbbVie in Q4 2013 and has held it in 50 quarters since.
Blue Fin Capital's AbbVie position peaked at $3.81M in Q3 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Blue Fin Capital's 13F filing for Q1 2026, filed 28 May 2026.